Shi Guolin, Lu Xiao, Wang Guowei, Qian Kai, Peng Xiaokang, Zhu Yangyang, Wu Jiaxu, Ke Haiyong, Chen Li, Zheng Yuanhang, Yang Tao, Shi Xiaoying, Huang Pintong
Department of Ultrasound in Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310009, People's Republic of China.
Post-Doctoral Research Center, Zhejiang SUKEAN Pharmaceutical Co., Ltd, Hangzhou, 311228, People's Republic of China.
Drug Des Devel Ther. 2025 Apr 10;19:2779-2794. doi: 10.2147/DDDT.S511158. eCollection 2025.
capsule (), listed in the Chinese Pharmacopoeia, has been employed for the treatment of infectious diarrhea. Nevertheless, the precise mechanism of remains to be elucidated.
This work was to investigate the antibacterial mode and therapeutic mechanism of towards infected diarrhea.
HPLC identified the primary chemical constituents of . A model of diarrhea was induced via injection. The impact of on -induced diarrhea was evaluated using a diarrhea score in Babl/c mice. The integrity of the intestinal barrier was assessed through staining and measuring levels of specific proteins. Furthermore, immunofluorescence staining was conducted to identify tight junction proteins in the small intestinal tissue. The full-length 16S rRNA was used to examine gut microbiota. Network pharmacology, molecular docking, and molecular dynamic simulation were used to investigate the impact of on diarrhea-related inflammation and quantify the expression levels of IL-6 and TNF- in the blood and small intestine. The in vivo antibacterial activity and mode of action of were also investigated using IVIS imaging, transmission electron microscopy, scanning electron microscopy, and molecular dynamic simulation.
exhibited a positive effect on infected diarrhea. The content of IL-6 and TNF- in mice with was significantly reduced. Additionally, could restore the intestinal barrier function by reversing small intestine structure and up-regulating the expression of tight junction proteins. The significantly inhibit pathogenic bacteria and restore the gut microbiota diversity. IVIS Imaging System was visually observed significant antibacterial efficacy of in vivo. The disrupted the cell membrane system of through the interaction between bioactive molecule and bilayer.
normalized the gut barrier function, reshaped gut microbiota balance, suppressed the inflammatory pathways, and inhibited the bacterial activity, thereby relieving the diarrhea caused by .
胶囊()被列入《中国药典》,已用于治疗感染性腹泻。然而,其确切机制仍有待阐明。
本研究旨在探讨其对感染性腹泻的抗菌模式和治疗机制。
采用高效液相色谱法鉴定其主要化学成分。通过注射诱导腹泻模型。使用腹泻评分评估其对诱导的腹泻在Babl/c小鼠中的影响。通过染色和测量特定蛋白质水平评估肠道屏障的完整性。此外,进行免疫荧光染色以鉴定小肠组织中的紧密连接蛋白。使用全长16S rRNA检测肠道微生物群。采用网络药理学、分子对接和分子动力学模拟研究其对腹泻相关炎症的影响,并量化血液和小肠中IL-6和TNF-的表达水平。还使用IVIS成像、透射电子显微镜、扫描电子显微镜和分子动力学模拟研究其体内抗菌活性和作用方式。
对感染性腹泻有积极作用。感染小鼠中IL-6和TNF-的含量显著降低。此外,可通过逆转小肠结构和上调紧密连接蛋白的表达来恢复肠道屏障功能。显著抑制病原菌并恢复肠道微生物群多样性。IVIS成像系统在体内直观观察到其显著的抗菌效果。通过生物活性分子与双层之间的相互作用破坏了的细胞膜系统。
可使肠道屏障功能正常化,重塑肠道微生物群平衡,抑制炎症途径,并抑制细菌活性,从而缓解由引起的腹泻。